Neupulse Raises £3M to Accelerate Neurotherapeutic Device for…

Team S · 2026-04-11T14:26:38.000Z

UK-based healthtech startup Neupulse has raised £3 million in new funding, signaling strong investor confidence in next-generation neurotherapeutic solutions aimed at addressing unmet needs in brain health. The funding round was led by Eos Advisory and the Midlands Engine Investment Fund II, managed by Mercia Ventures, with participation from both new and existing investors, highlighting continued backing from institutional healthcare-focused capital. Neupulse is developing a non-drug wearable device designed to help manage symptoms of Tourette Syndrome, a condition that currently relies heavily on medication and behavioral therapy. The company’s technology delivers controlled electrical stimulation to the wrist, aiming to regulate brain activity associated with involuntary tics and provide patients with a more accessible and user-friendly treatment option. The newly raised capital will be used to scale sales, advance product development, and support regulatory milestones as the company moves toward commercial launch, expected in 2026. The funding will also enable further clinical validation and early-stage commercialization efforts to ensure the technology reaches patients who need it most. As demand grows for non-invasive and clinically validated treatments in neurological care, Neupulse is positioning itself within the emerging neurotech and digital therapeutics space. The company’s approach reflects a broader shift toward personalized, device-based interventions that can complement or replace traditional pharmaceutical treatments. With this funding, Neupulse aims to transition from development to market deployment, positioning itself as a key innovator in the neurotherapeutics landscape and contributing to the evolution of modern brain health treatment solutions.

Member Login Get Access

Neupulse Raises £3M to Accelerate Neurotherapeutic Device for… | Newnex